🔗 Permalink

Inventor profile of:

Ian MacLachlan

City:

Mission

Country:

Canada

Published Applications:

Last publication date:

2024-09-26

Top Assignees for applications by Ian MacLachlan

The entities that hold a legal rights for patent applications filed by inventor MacLachlan Ian:

PROTIVA BIOTHERAPEUTICS, INC. 35 Burnaby, Canada
Protiva Biotherapeutics, Inc. 28 Burnaby, BC Canada
ARBUTUS BIOPHARMA CORPORATION 6 Vancouver, Canada
ARBUTUS BIOPHARMA CORPORATION 4 Vancouver, BC Canada
Arbutus Biopharma Corporation 2 Burnaby, BC Canada
ALNYLAM PHARMACEUTICALS, INC. 2 Cambridge, MA United States
The USA, as represented by the Secretary, Dept.of Health and Human Services 1 Rockville, MD United States
United States Army Medical Research and Materiel Command 1 Frederick, MD United States
Protiva Biotherapeutics,Inc. 1 Burnaby, BC Canada
Protiva Biotherapeutics, Inc. 1 Burnaby, United Kingdom
ARBUTUS BIOPHARMA CORPORATION 1 Warminster, PA United States
The United States of America, as represented by the Secretary, Department of Health and Human Services 1 Washington, DC United States
Protiva Biotherapeutics, Inc. 1 Burnaby, British Columbia, Canada
The United States Army Medical Research and Materiel Command 1 Washington, DC United States
TRUSTEES OF BOSTON UNIVERSITY 1 Boston, MA United States
The United States of America, as represented by the Secretary, Dept. of Health and Human Services 1 Bethesda, MD United States
Department of Health and Human Services 1 Rockville, MD United States
The United States of America, as represented by the Secretary, Department of Health and Human Services 1 Bethesda, MD United States
Protive Biotherapeutics, Inc. 1 Burnaby ,BC, Canada

Recent patent applications by MacLachlan Ian

Ian MacLachlan from Mission, CA has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2024-09-26

US20240316206A1

Human necessities

NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS

#2 | 2024-05-09

US20240148875A1

Human necessities

Lipid formulations for delivery of therapeutic agents

#3 | 2024-03-28

US20240100166A1

Human necessities

NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS

#4 | 2023-11-23

US20230372245A1

Human necessities

LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY

#5 | 2023-08-10

US20230248831A1

Human necessities

Lipid formulations for delivery of therapeutic agents

#6 | 2023-06-01

US20230165973A1

Human necessities

COMPOSITIONS AND METHODS FOR DELIVERING MESSENGER RNA

#7 | 2021-09-02

US20210267895A1

Human necessities

Lipid formulations for nucleic acid delivery

#8 | 2021-07-22

US20210220274A1

Human necessities

NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY

#9 | 2020-09-24

US20200297870A1

Human necessities

COMPOSITIONS AND METHODS FOR DELIVERING MESSENGER RNA

#10 | 2020-04-16

US20200113832A1

Human necessities

NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY

#11 | 2019-08-08

US20190240339A1

Human necessities

Lipid formulations for delivery of therapeutic agents

#12 | 2019-06-06

US20190167586A1

Human necessities

LIPOSOMAL APPARATUS AND MANUFACTURING METHODS

#13 | 2019-03-07

US20190071669A1

Chemistry; metallurgy

LIPID ENCAPSULATING INTERFERING RNA

#14 | 2018-04-05

US20180092848A1

Human necessities

NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY

#15 | 2018-03-29

US20180085312A1

Human necessities

NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY

#16 | 2018-03-15

US20180071397A1

Human necessities

NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS

#17 | 2018-01-18

US20180016583A1

Chemistry; metallurgy

Compositions and methods for silencing hepatitis B virus gene expression

#18 | 2017-09-14

US20170258719A1

Human necessities

LIPOSOMAL APPARATUS AND MANUFACTURING METHODS

#19 | 2017-02-16

US20170042814A1

Human necessities

NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY

#20 | 2016-09-15

US20160264971A1

Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS GENE EXPRESSION

#21 | 2016-04-28

US20160115483A1

Chemistry; metallurgy

SILENCING OF POLO-LIKE KINASE EXPRESSION USING INTERFERING RNA

#22 | 2016-04-28

US20160115477A1

Chemistry; metallurgy

Lipid encapsulating interfering RNA

#23 | 2016-03-17

US20160076035A1

Chemistry; metallurgy

Compositions and methods for silencing marburg virus gene expression

#24 | 2015-12-31

US20150374834A1

Human necessities

Lipid formulations for delivery of therapeutic agents to solid tumors

#25 | 2015-11-05

US20150315584A1

Chemistry; metallurgy

Compositions and methods for silencing apolipoprotein C-III expression

#26 | 2015-06-18

US20150164799A1

Human necessities

Lipid formulations for nucleic acid delivery

#27 | 2014-10-02

US20140294937A1

Human necessities

Lipid compositions for nucleic acid delivery

#28 | 2014-09-04

US20140248338A1

Chemistry; metallurgy

Compositions and methods for silencing aldehyde dehydrogenase

#29 | 2014-06-26

US20140179756A1

Chemistry; metallurgy

Modified siRNA molecules and uses thereof

#30 | 2014-06-12

US20140161894A1

Chemistry; metallurgy

SIRNA SILENCING OF GENES EXPRESSED IN CANCER

#31 | 2014-03-06

US20140065228A1

Chemistry; metallurgy

Lipid formulations for nucleic acid delivery

#32 | 2014-02-13

US20140044772A1

Human necessities

Liposomal apparatus and manufacturing methods

#33 | 2013-07-11

US20130178511A1

Chemistry; metallurgy

SILENCING OF CSN5 GENE EXPRESSION USING INTERFERING RNA

#34 | 2013-07-04

US20130172405A1

Chemistry; metallurgy

Compositions and methods for silencing SMAD4

#35 | 2013-06-04

US13077856

Compositions and methods for silencing genes involved in hemorrhagic fever

#36 | 2013-05-16

US20130123339A1

Human necessities

Compositions and methods for silencing apolipoprotein B

#37 | 2013-05-16

US20130122104A1

Human necessities

NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS

#38 | 2013-03-14

US20130065939A1

Chemistry; metallurgy

Compositions and methods for silencing genes expressed in cancer

#39 | 2013-01-24

US20130022649A1

Chemistry; metallurgy

SNALP FORMULATIONS CONTAINING ANTIOXIDANTS

#40 | 2012-12-27

US20120328668A1

Chemistry; metallurgy

Modified siRNA molecules and uses thereof

#41 | 2012-08-09

US20120202871A1

Human necessities

Cationic lipids and methods for the delivery of therapeutic agents

#42 | 2012-07-19

US20120184595A1

Chemistry; metallurgy

Compositions and methods for silencing apolipoprotein C-III expression

#43 | 2012-07-19

US20120183581A1

Human necessities

Lipid formulations for nucleic acid delivery

#44 | 2012-03-08

US20120058188A1

Human necessities

LIPID ENCAPSULATED INTERFERING RNA

#45 | 2011-09-15

US20110224418A1

Chemistry; metallurgy

MODIFIED sIRNA MOLECULES AND USES THEREOF

#46 | 2011-09-08

US20110216622A1

Human necessities

Liposomal apparatus and manufacturing method

#47 | 2011-08-18

US20110201667A1

Chemistry; metallurgy

Compositions and methods for silencing Ebola virus gene expression

#48 | 2011-08-11

US20110195127A1

Human necessities

Compositions and methods for silencing apolipoprotein B

#49 | 2011-08-04

US20110189300A1

Human necessities

siRNA SILENCING OF APOLIPOPROTEIN B

#50 | 2011-07-21

US20110178155A1

Chemistry; metallurgy

Silencing of CSN5 gene expression using interfering RNA

#51 | 2011-07-21

US20110177131A1

Chemistry; metallurgy

siRNA SILENCING OF FILOVIRUS GENE EXPRESSION

#52 | 2011-03-31

US20110076335A1

Human necessities

Lipid formulations for nucleic acid delivery

#53 | 2011-03-24

US20110071208A1

Human necessities

LIPID ENCAPSULATED DICER-SUBSTRATE INTERFERING RNA

#54 | 2010-05-27

US20100130588A1

Human necessities

Lipid formulations for nucleic acid delivery

#55 | 2009-11-26

US20090291131A1

Chemistry; metallurgy

Silencing of polo-like kinase expression using interfering RNA

#56 | 2009-10-29

US20090270481A1

Chemistry; metallurgy

Modified siRNA molecules and uses thereof

#57 | 2009-06-11

US20090149403A1

Chemistry; metallurgy

SiRNA silencing of genes expressed in cancer

#58 | 2008-10-09

US20080249046A1

Chemistry; metallurgy

Modified siRNA molecules and uses thereof

#59 | 2008-07-17

US20080171716A1

Chemistry; metallurgy

NUCLEIC ACID MODULATION OF TOLL-LIKE RECEPTOR-MEDIATED IMMUNE STIMULATION

#60 | 2007-09-20

US20070218122A1

Human necessities

siRNA silencing of influenza virus gene expression

#61 | 2007-06-14

US20070135372A1

Chemistry; metallurgy

Modified siRNA molecules and uses thereof

#62 | 2007-03-08

US20070054873A1

Human necessities

Glucocorticoid modulation of nucleic acid-mediated immune stimulation

#63 | 2007-02-22

US20070042031A1

Human necessities

Systems and methods for manufacturing liposomes

#64 | 2006-10-26

US20060240093A1

Human necessities

Lipid encapsulated interfering RNA

#65 | 2006-02-02

US20060025366A1

Chemistry; metallurgy

Compositions comprising immunostimulatory siRNA molecules and DLinDMA or DLenDMA

InventorID:

52557 ⎘